Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis

Yang,Guang; Yang,Lu; Yang,Xiaofan; Shi,Xiuyu; Wang,Jing; Liu,Yujie; Ju,Jun; Zou,Liping

doi:10.3892/etm.2014.2093

Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis

Authors:
- Guang Yang
- Lu Yang
- Xiaofan Yang
- Xiuyu Shi
- Jing Wang
- Yujie Liu
- Jun Ju
- Liping Zou
View Affiliations

Affiliations: Department of Pediatrics, Chinese PLA General Hospital, Beijing 100853, P.R. China, Special Care Medical Center, Navy General Hospital of PLA, Beijing 100048, P.R. China
Published online on: November 27, 2014 https://doi.org/10.3892/etm.2014.2093
Pages: 626-630

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibitors of mammalian target of rapamycin (mTOR) are increasingly used as therapy for pediatric patients with tuberous sclerosis complex (TSC). The uncertainty over the efficacy and safety of mTOR inhibitor therapy for the treatment of pediatric patients with TSC emphasizes the necessity for a synthesis of existing evidence. The aim of this study was to assess the efficacy and safety of mTOR inhibitor therapy for the treatment of pediatric patients with TSC. The PubMed, EmBase and Cochrane Library electronic databases were searched, and studies of mTOR inhibitor therapy and non‑mTOR inhibitor therapy in pediatric patients with TSC (<18 years old) were selected. Eleven studies met the inclusion criteria. There was evidence of a significantly increased response rate in pediatric patients with TSC treated with mTOR inhibitor therapy compared with those treated with non‑mTOR inhibitor therapy (odds ratio, 24.71; 95% confidence interval, 7.46‑81.72; P<0.001). The majority of studies reported few adverse events. There was an increased incidence of mouth ulceration, stomatitis, convulsion and pyrexia in pediatric patients with TSC treated with mTOR inhibitor therapy. In conclusion, mTOR inhibitor therapy is an efficacious and safe treatment for pediatric patients with TSC.

View Figures

View References

1	Borkowska J, Schwartz RA, Kotulska K and Jozwiak S: Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 50:13–20. 2011. View Article : Google Scholar
2	Osborne JP, Fryer A and Webb D: Epidemiology of tuberous sclerosis. Ann NY Acad Sci. 615:125–127. 1991. View Article : Google Scholar : PubMed/NCBI
3	Crino PB, Nathanson KL and Henske EP: The tuberous sclerosis complex. N Engl J Med. 355:1345–1356. 2006. View Article : Google Scholar : PubMed/NCBI
4	Benyounes N, Fohlen M, Devys JM, et al: Cardiac rhabdomyomas in tuberous sclerosis patients: a case report and review of the literature. Arch Cardiovasc Dis. 105:442–445. 2012. View Article : Google Scholar : PubMed/NCBI
5	Hunter AG, Nezarati MM and Velsher L: Absence of signs of systemic involvement in four patients with bilateral multiple facial angiofibromas. Am J Med Genet A. 152A:657–664. 2010. View Article : Google Scholar : PubMed/NCBI
6	Sterman H, Furlan AB, Matushita H and Teixeira MJ: Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. Case report and review of literature. Childs Nerv Syst. 29:335–339. 2013. View Article : Google Scholar
7	Meraj R, Wikenheiser-Brokamp KA, Young LR and McCormack FX: Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med. 33:486–497. 2012. View Article : Google Scholar : PubMed/NCBI
8	Crino PB: Evolving neurobiology of tuberous sclerosis complex. Acta Neuropathol. 125:317–332. 2013. View Article : Google Scholar : PubMed/NCBI
9	Franz DN and Weiss BD: Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep. 12:294–301. 2012. View Article : Google Scholar : PubMed/NCBI
10	Davies DM, Johnson SR, Tattersfield AE, et al: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 358:200–203. 2008. View Article : Google Scholar : PubMed/NCBI
11	Curatolo P and Moavero R: mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol. 10:404–415. 2012. View Article : Google Scholar :
12	Franz DN: Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics. 7:211–221. 2013.PubMed/NCBI
13	Pressey JG, Wright JM, Geller JI, et al: Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 54:1035–1037. 2010.PubMed/NCBI
14	Lam C, Bouffet E, Tabori U, et al: Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer. 54:476–479. 2010. View Article : Google Scholar
15	Hofbauer GF, Marcollo-Pini A, Corsenca A, et al: The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 159:473–475. 2008. View Article : Google Scholar : PubMed/NCBI
16	Franz DN, Leonard J, Tudor C, et al: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 59:490–498. 2006. View Article : Google Scholar : PubMed/NCBI
17	Birca A, Mercier C and Major P: Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr. 6:381–384. 2010. View Article : Google Scholar : PubMed/NCBI
18	Staehler M, Sauter M, Helck A, et al: Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis. Int Urol Nephrol. 44:1657–1661. 2012. View Article : Google Scholar : PubMed/NCBI
19	Sparagana SP, Wilkes DC, Thompson CE and Bowers DC: Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus. Pediatr Neurol. 42:443–446. 2010. View Article : Google Scholar : PubMed/NCBI
20	Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6:e10000972009. View Article : Google Scholar : PubMed/NCBI
21	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
22	Higgins JPT and Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.10. The Cochrane Collaboration; Oxford: 2011
23	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
24	Ades AE, Lu G and Higgins JP: The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 25:646–654. 2005. View Article : Google Scholar : PubMed/NCBI
25	Franz DN, Belousova E, Sparagana S, et al: Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 381:125–132. 2013. View Article : Google Scholar
26	Foster RS, Bint LJ and Halbert AR: Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 53:52–56. 2012. View Article : Google Scholar : PubMed/NCBI
27	Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, et al: Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma. J Eur Acad Dermatol Venereol. 26:1315–1318. 2012. View Article : Google Scholar
28	Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S and Katayama I: A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 165:912–916. 2011. View Article : Google Scholar : PubMed/NCBI
29	Ehninger D: From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches. Neuropharmacology. 68:97–105. 2013. View Article : Google Scholar
30	Han JM and Sahin M: TSC1/TSC2 signaling in the CNS. FEBS Lett. 585:973–980. 2011. View Article : Google Scholar : PubMed/NCBI
31	Yang H, Wang X, Zhang Y, et al: Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity. J Cell Physiol. 229:17–26. 2014.
32	Guo Y and Kwiatkowski DJ: Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol Cancer Res. 11:467–473. 2013. View Article : Google Scholar : PubMed/NCBI
33	Cambiaghi M, Cursi M, Magri L, et al: Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex. Neuropharmacology. 67:1–7. 2013. View Article : Google Scholar
34	Zhang Y and Zheng XF: mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 11:594–603. 2012. View Article : Google Scholar : PubMed/NCBI
35	Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012. View Article : Google Scholar : PubMed/NCBI
36	Guba M, Yezhelyev M, Eichhorn ME, et al: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 105:4463–4469. 2005. View Article : Google Scholar : PubMed/NCBI
37	Frost P, Berlanger E, Mysore V, et al: Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol. 2013:8970252013. View Article : Google Scholar : PubMed/NCBI
38	Roa J, Garcia-Galiano D, Castellano JM, et al: Metabolic control of puberty onset: new players, new mechanisms. Mol Cell Endocrinol. 324:87–94. 2010. View Article : Google Scholar